NCT05681247 is a Phase 1 clinical trial of ezetimibe tablet in Hyperlipidemias, sponsored by The Affiliated Hospital of Qingdao University.

Who is sponsoring NCT05681247?

NCT05681247 is sponsored by The Affiliated Hospital of Qingdao University.

What drugs are being tested in NCT05681247?

Interventions in NCT05681247: ezetimibe tablet, ezetimibe tablet(Ezetrol ®).

What condition does NCT05681247 study?

NCT05681247 studies Hyperlipidemias.

Is NCT05681247 still recruiting?

NCT05681247 is currently completed. Last updated 12 January 2023.

Last reviewed 2023-01-12 · How we verify

NCT05681247

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Completed Phase 1 Last updated 12 January 2023

What this trial tests

Phase 1 trial testing ezetimibe tablet in Hyperlipidemias in 59 participants. Completed in 7 March 2018.

Timeline

17 December 2017

Primary endpoint
29 January 2018

7 March 2018

Quick facts

Lead sponsor	The Affiliated Hospital of Qingdao University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	59
Start date	17 December 2017
Primary completion	29 January 2018
Estimated completion	7 March 2018
Sites	1 location across China

Drugs / interventions tested

ezetimibe tablet
ezetimibe tablet(Ezetrol ®) — full drug profile →

Conditions studied

Hyperlipidemias — all drugs for Hyperlipidemias →

Sponsor

The Affiliated Hospital of Qingdao University

Who can join

18 and older, any sex, with Hyperlipidemias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was conducted to assess the bioequivalence of the ezetimibe tablet to Ezetrol ® in healthy Chinese volunteers and estimate the pharmacokinetic proﬁles of ezetimibe tablet.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects.
Sun F, Liu Y, Li T, Lin P, et al · · 2023 · cited 4× · PMID 36737825 · DOI 10.1186/s40360-023-00649-y
Nano-structured strategies in combatting neurodegeneration.
Prasanth MI, Mallya AR, Cho WC, Mundekkad D. · · 2025 · PMID 41409624 · DOI 10.3389/fbioe.2025.1638668

Verify or expand the search:

Other recruiting trials for Hyperlipidemias

Currently open trials in the same condition.

NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting

Other The Affiliated Hospital of Qingdao University trials

Trials by the same sponsor.

NCT07485920 — A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedani · Phase 4 · not yet recruiting
NCT07465861 — Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction · NA · not yet recruiting
NCT07453771 — Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma · NA · not yet recruiting
NCT07404709 — Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Ste · Phase 1, PHASE2 · not yet recruiting
NCT07167342 — The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05681247 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Qingdao University
Last refreshed: 12 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05681247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing